News
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than 57%. And since the beginning of 2025, the company’s share price has declined more than 35%. As of the time of this writing, NVO shares are down just over 20% this morning to $55.17 per share.
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
In a release on Tuesday, Novo Nordisk cut its expected full-year sales growth to 8%-14%, down from the 13%-21% it had ...
Shares in the maker of Ozempic crashed to three-year low after the pharma giant warned its injections were losing ground to ...
Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...
Novo Nordisk has launched its anti-obesity drug Wegovy in India, which has become a key market for the company. Having ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback